Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011)
Nektar Therapeutics (NKTR) posted quarterly Convertible Debt of $215.0 million for Q4 2011, little changed year-over-year from $215.0 million in Q4 2010, and little changed quarter-over-quarter from $215.0 million in Q2 2011.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011) Analysis & Trends
Nektar Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $215.0 million for Q4 2011.
- In Q4 2011, Convertible Debt changed 0.0% year-over-year to $215.0 million; the TTM figure through Dec 2011 stood at $215.0 million (changed 0.0% YoY), while the FY2011 annual figure was $215.0 million, changed 0.0% from the prior year.
- Convertible Debt for Q4 2011 stood at $215.0 million, roughly flat from $215.0 million in the prior quarter.
- The five-year high for Convertible Debt was $215.0 million in Q4 2010, with the low at $215.0 million in Q4 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2011 | 214.96 Mn |
| Jun 30, 2011 | 214.96 Mn |
| Mar 31, 2011 | 214.96 Mn |
| Dec 31, 2010 | 214.96 Mn |